HC Wainwright Issues Positive Forecast for DRTS Earnings

Alpha Tau Medical Ltd. (NASDAQ:DRTS - Free Report) - Equities researchers at HC Wainwright raised their Q2 2025 earnings per share estimates for Alpha Tau Medical in a report issued on Tuesday, April 29th. HC Wainwright analyst Y. Chen now anticipates that the company will post earnings of ($0.12) per share for the quarter, up from their prior estimate of ($0.13). HC Wainwright currently has a "Buy" rating and a $9.00 target price on the stock. The consensus estimate for Alpha Tau Medical's current full-year earnings is ($0.45) per share. HC Wainwright also issued estimates for Alpha Tau Medical's Q3 2025 earnings at ($0.11) EPS, Q4 2025 earnings at ($0.11) EPS and FY2025 earnings at ($0.47) EPS.

Alpha Tau Medical Trading Up 0.8 %

Shares of NASDAQ:DRTS traded up $0.02 on Thursday, reaching $2.62. 9,011 shares of the company were exchanged, compared to its average volume of 47,182. The company has a 50-day moving average of $2.63 and a 200-day moving average of $2.86. Alpha Tau Medical has a 1-year low of $1.75 and a 1-year high of $4.39. The firm has a market cap of $184.40 million, a price-to-earnings ratio of -6.09 and a beta of 0.92.

Alpha Tau Medical (NASDAQ:DRTS - Get Free Report) last released its earnings results on Wednesday, March 12th. The company reported ($0.13) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.13).

Institutional Investors Weigh In On Alpha Tau Medical

A number of institutional investors and hedge funds have recently modified their holdings of DRTS. Renaissance Technologies LLC raised its position in Alpha Tau Medical by 188.7% during the fourth quarter. Renaissance Technologies LLC now owns 41,000 shares of the company's stock worth $127,000 after acquiring an additional 26,800 shares during the last quarter. Northern Trust Corp lifted its holdings in shares of Alpha Tau Medical by 112.6% during the 4th quarter. Northern Trust Corp now owns 48,666 shares of the company's stock worth $151,000 after acquiring an additional 25,770 shares during the period. Finally, Levin Capital Strategies L.P. boosted its position in shares of Alpha Tau Medical by 2.3% in the fourth quarter. Levin Capital Strategies L.P. now owns 314,514 shares of the company's stock worth $975,000 after acquiring an additional 7,189 shares during the last quarter. Institutional investors and hedge funds own 2.65% of the company's stock.

About Alpha Tau Medical

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others.